New Data on Endeavor
Stent's Long-Term Safety and Efficacy to Be Featured at Interventional
Cardiology Congress
4,000-Patient Milestone in Medtronic CoreValve Program Also Expected
to Coincide with EuroPCR09
|
|
May 15, 2009 -- Minneapolis --
Medtronic, Inc. (NYSE: MDT), today announced planned highlights of
new data presentations scheduled for the 2009 PCR meeting that feature
the company’s cardiovascular innovations. From late breaking
clinical trials, extensive new data on the Endeavor® Drug-Eluting
Stent (DES) will be presented, which shows unprecedented long-term
efficacy for a DES.
Also featured are new data on Medtronic’s CoreValve® transfemoral
and subclavian aortic valve system. Medtronic also anticipates that
PCR 2009 will coincide with the 4,000th successful CoreValve implant.
Important data on the long-term efficacy and durable safety of the
Endeavor DES will be presented in the following late-breaking clinical
trial sessions:
Tuesday, May 19
- ENDEAVOR II and ENDEAVOR Pooled five-year data by Dr. D. Kandzari
Thursday , May 21
- DATE Registry on early discontinuation of antiplatelet therapy
by Dr. H. Gwon.
Additional data related to Medtronic’s
cardiovascular medical technologies will also be released in the
following oral and poster
contributions starting Tuesday, May 19:
- E-Five one-year ACS subset data by Prof. M. Rothman
- Medtronic CoreValve subclavian transcatheter aortic valve replacement
by Dr. Jean-Claude Laborde
- E-Five one- and two-year data by Prof. I. Meredith
In addition, Medtronic will feature highlights
of its current and future cardiovascular innovations at PCR (booth
numbers D04 and F09).
PCR takes place in Barcelona, Spain, May 19–22.
About Medtronic
Medtronic, Inc. (www.medtronic.com),
headquartered in Minneapolis, is the global leader in medical technology – alleviating
pain, restoring health and extending life for millions of people
around the world.
Note: The Medtronic CoreValve System is not currently available
for sale or clinical trials in the United States.
Any forward-looking statements are subject
to risks and uncertainties such as those described in Medtronic’s
Annual Report on Form 10-K for the year ended April 25, 2008. Actual
results may differ
materially from anticipated results.
Source: Medtronic,
Inc.
|